Here are five things to know:
1. The company’s worldwide sales hit $2.2 billion, a 1.4 percent decrease over the same period last year. The U.S. sales dropped 2.6 percent to $1.3 billion while international sales were up 0.4 percent at $930 million.
2. Hip sales were up 2.9 percent to $360 million, driven by the international sales that jumped nearly 5 percent to $149 million. U.S. sales were up 1.4 percent for the quarter to $211 million.
3. Knee sales were relatively flat, dropping just 0.8 percent to $382 million. U.S. knee sales were down 3 percent to $229 million, partially offset by 2.7 percent gains in international knee sales, which hit $153 million.
4. DePuy Synthes spine and other sales dropped 7.7 percent, led by a 9.2 percent decrease in international sales to $347 million. U.S. spine and other sales also dropped 6.6 percent to $498 million.
5. Trauma sales increased 5 percent, driven by 11 percent growth in international sales to hit $281 million. U.S. trauma sales increased 1 percent to $394 million.
More articles on orthopedic devices:
How 8 big spine companies’ Q2 compared & what to expect in the future
17 key players in the global spine biologics market
Kathie Lenzen joins Xtant Medical as CFO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
